Literature DB >> 18635312

Histone deacetylase inhibitors and genomic instability.

Grégory Eot-Houllier1, Géraldine Fulcrand, Laura Magnaghi-Jaulin, Christian Jaulin.   

Abstract

Histone deacetylase inhibitors (HDACIs) are a promising new class of anticancer drugs. However, their mechanism of action has not been fully elucidated. Most studies have investigated the effect of HDACIs on the regulation of gene transcription. HDAC inhibition also leads to genomic instability by a variety of mechanisms. This phenomenon, which has been largely overlooked, may contribute to the cytotoxic effects of these drugs. Indeed, HDACIs sensitize DNA to exogenous genotoxic damage and induce the generation of reactive oxygen species. Moreover, HDACIs target mitosis resulting in chromosome segregation defects. Here, we review the effects of HDACI treatment on DNA damage and repair, and chromosome segregation control.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635312     DOI: 10.1016/j.canlet.2008.06.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  50 in total

Review 1.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

Review 2.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

3.  Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors.

Authors:  Hazem Abdelkarim; Raghupathi Neelarapu; Antonett Madriaga; Aditya S Vaidya; Irida Kastrati; Bhargava Karumudi; Yue-Ting Wang; Taha Y Taha; Gregory R J Thatcher; Jonna Frasor; Pavel A Petukhov
Journal:  ChemMedChem       Date:  2017-11-30       Impact factor: 3.466

Review 4.  Chromatin dynamics underlying latent responses to xenobiotics.

Authors:  Jonathan Moggs; Rémi Terranova
Journal:  Toxicol Res (Camb)       Date:  2018-02-28       Impact factor: 3.524

5.  Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

Authors:  J-H Lee; M L Choy; L Ngo; S S Foster; Paul A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

Review 6.  Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review.

Authors:  Prabhat Singh; Raghuvir Singh Tomar; Srikanta Kumar Rath
Journal:  Mol Biol Rep       Date:  2015-06-02       Impact factor: 2.316

Review 7.  Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.

Authors:  Paul A Marks
Journal:  Biochim Biophys Acta       Date:  2010-06-08

8.  Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors.

Authors:  Sai-Wen Tang; Anish Thomas; Junko Murai; Jane B Trepel; Susan E Bates; Vinodh N Rajapakse; Yves Pommier
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

9.  6-Methoxyquinoline complexes as lung carcinoma agents: induction of oxidative damage on A549 monolayer and multicellular spheroid model.

Authors:  J F Cadavid-Vargas; C Villa-Pérez; M C Ruiz; I E León; G C Valencia-Uribe; D B Soria; S B Etcheverry; A L Di Virgilio
Journal:  J Biol Inorg Chem       Date:  2019-01-30       Impact factor: 3.358

10.  Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia.

Authors:  Guang Bai; Dong Wei; Shiping Zou; Ke Ren; Ronald Dubner
Journal:  Mol Pain       Date:  2010-09-07       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.